<DOC>
	<DOCNO>NCT02328222</DOCNO>
	<brief_summary>BACKGROUND : Non-steroid maintenance immunosuppression transplantation improve long-term lipid hemodynamic profile without severe acute rejection ( AR ) event alter graft function survival . Our objective evaluate effect early steroid withdrawal ( ESW ) frequency severity AR use immunosuppressive scheme consist mycophenolate ( MMF ) tacrolimus ( TAC ) combination induction treatment basiliximab . METHODS : A randomized clinical trial perform first renal transplant recipient . In ESW group , patient select corticosteroid treatment withdrawal fifth day post-transplantation . In Control group , patient continue steroid treatment .</brief_summary>
	<brief_title>ESTEROID WITHDRAWAL STUDY , SAFETY AND EFFICACY IN RENAL TRANPLANTATION</brief_title>
	<detailed_description>INTRODUCTION New immunosuppressant drug lower early acute rejection ( AR ) rate controversial result improve long-term renal graft patient survival ( 1-3 ) . An ideal maintenance immunosuppressant treatment improve long-term renal graft function survival determine ( 4 ) . With new potent immunosuppressant available , new strategy develop reduce eliminate use steroid transplantation due important side effect lack benefit long-term graft patient survival ( 5-8 ) . Immunosuppression minimization strategy lead possibility early steroid withdrawal similar result AR incidence , function , renal graft well patient survival among continue steroid treatment transplantation ( 9-21 ) . Current clinical practice guideline kidney disease improve global outcome ( KDIGO ) suggest steroid could withdraw patient low immunological risk kidney transplantation receive induction immunosuppressive therapy ( 22 ) . However , recent meta-analysis indicate steroid removal withdrawal renal transplantation could link risk kidney graft AR immunosuppression regimen ( 5 ) . Nevertheless , kidney graft rejection non-steroidal immunosuppression show mild rejection characteristic negative impact function graft patient survival , type intervention still controversial ( 5 ) . In Mexico , information concern therapeutic intervention steroid withdrawal transplantation , common practice . In hospital , high percentage kidney transplant consist living-related donor low immunological risk , case steroid based-immunosuppressive regimen mycophenolate mofetil ( MMF ) calcineurin inhibitor ; Tacrolimus ( TAC ) cyclosporine ( CsA ) use maintenance immunosuppressive therapy ( 23 ) . We believe steroid withdrawal transplantation could beneficial due low immunological risk high risk diabetes , obesity , metabolic syndrome population ( 24 , 25 ) . Thus , objective study ass compare effect early steroid withdrawal frequency severity AR impact function graft survival . MATERIALS AND METHODS The study perform Division Transplantation Specialties Hospital , Western National Medical Center , IMSS Guadalajara , Jalisco follow ethical norm Helsinki Declaration approval local ethic committee write informed consent . STUDY DESIGN A randomized , open-label , control clinical trial patient single kidney transplant use live donor ( related non-related ) perform June 2010 June 2011 . The patient underwent immunosuppressive maintenance treatment either without prednisone ( PDN ) ( Early steroid withdrawal group ) PDN ( Control group ) . All patient 18 year age panel reactive antibody ( PRA ) class I II HLA &lt; 20 % . We exclude patient co-morbidities require use steroid , delay graft function AR 5 day post-transplantation , along patient decide leave study . Variables age gender recipient donor , family history diabetes mellitus , pregnancy , weight , height , blood pressure , glucose level , lipid profile , cause renal disease , HLA histocompatibility , PRA , cytomegalovirus ( CMV ) serostatus , drug treatment ( anti-hypertensive agent , euglycemic agent , statin ) obtain , date diagnosis dyslipidemia , high systemic blood pressure , post-transplantation diabetes mellitus ( PTDM ) . Posttransplant assessment make 3 , 6 , 9 , 12 month . Information collect included date transplant , type donor , cold warm ischemic time , immunosuppressant-induction ( basiliximab ) maintenance ( TAC , MMF , PDN ) , date AR diagnosis , anti-rejection treatment ( methylprednisolone thymoglobulin ) . The number AR event , severity , presence chronic graft nephropathy define use Banff classification ( 26 ) . The histopathological analysis graft evaluate use protocolized percutaneous kidney biopsy 3 , 6 , 12 month post-transplantation . These biopsy perform patient clinically require , pathologist analyzed sample . The AR episode ( subclinical , borderline , Banff 1A ) ( 26 ) manage IV methylprednisolone ( MPD ) , 250 mg 1 g 3 5 day , polyclonal antibody ( thymoglobulin ) steroid-resistant AR severe AR ( 26 ) dose 1.5 mg/kg/day 7 10 day . In case humoral rejection , plasmapheresis 300 mg/m2 rituximab consider . Patients subject protocol require biopsy present histopathological evidence borderline change IA-Banff classification treat MPD continue study . Patients severe AR steroid-resistant AR exclude study ( analysis ) , steroid treatment restart AR event . Renal function determine follow method : MDRD-4 formula ( MDRD ( ml/min/1.73 m2 ) = 186 x ( creatinine /88.4 ) -1.154 x age-0.203 x 0.742 female ) ( 27 ) . TAC blood level measure via quantitative colorimetric analysis use blood EMIT ( enzyme-multiplied immunoassay technique ) 2000 Tacrolimus Assay ( Syva-SIEMENS ) . TAC level first 30 day maintain 9-15 ng / ml , day 31 365 , level 8-10 ng / ml consider appropriate . Class I II HLA PRAs determine transplantation use Flow-PRA ( One Lambda Inc , Canoga Park , CA , USA ) ; cut-off level &gt; 20 % consider positive . DEFINITIONS Early steroid withdrawal ( ESW ) define arbitrarily absence steroid fifth day post-transplantation . Post-transplantation diabetes mellitus ( PTDM ) hyperglycemic state posterior transplantation occur fast glucose &gt; 126 mg/dl two different occasion fast random glucose 200 mg/dl ( 28 ) . Systemic arterial hypertension ( SAH ) blood pressure exceed 140/90 mmHg , base two measurement two visit ( 29 ) . IMMUNOSUPPRESSION PROTOCOLS The immunosuppressive-induction scheme use study base 0.18 mg/kg/day TAC two dos , 2 g/day mycophenolate mofetil ( MMF ) per day two dos , 500 mg methylprednisolone surgery ( day zero ) , anti-interleukin 2 humanized monoclonal antibody ( 20 mg basiliximab ( SimulectÂ® ) first fourth day post-transplantation . Maintenance immunosuppression base 2 g/day MMF two dose 0.1-0.2 mg/kg/day TAC two dos ( dos modify accord serum level ) . Early steroid withdrawal perform follow : day zero post-transplantation ( DP 0 ) , 500 mg/day MPD ; ( DP 1 ) , 250 mg MPD ; ( DP 2 ) , 125 mg MPD ; ( DP 3 ) , 60 mg MPD ; ( DP 4 ) , 30 mg MPD ; ( DP 5 ) , steroid suspension . STATISTICAL ANALYSIS Continuous variable analyze use Student 's t-test , demographic categorical variable result difference group analyze use chi-square test . To estimate risk rejection steroid-withdrawal patient , logistic regression analysis perform . Rejection-free graft survival estimate use Kaplan-Meier survival analysis . Results consider significant p &lt; 0.05 . Statistical analysis perform use SPSS Statistical Package version 17 .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Over 18 year age Panel reactive antibody ( PRA ) class I II HLA &lt; 20 % . Any gender Living donor Patients comorbidities require use steroid , Delayed graft function AR 5 day posttransplantation , Along patient decide leave study . Multiorganic recipient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Early steroid withdrawal</keyword>
	<keyword>Acute allograft rejection</keyword>
	<keyword>Mycophenolate</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Basiliximab</keyword>
</DOC>